Elder Pharma targets $ one billion revenue from Japan

Elder Pharmaceuticals is targeting revenues of up to one billion dollars from the lucrative $ 70 billion Japanese pharma market. The company has recently received accreditation from Ministry of Health, Japan for its active pharmaceutical ingredients (API) plant at Patalganga and is planning to be an API and advanced intermediate supplier to the Japanese market.

It has already filed for new patents in these markets and expects the approvals in next six months. The company has also developed two products going off patent in the Japanese market in 2014. One of the products is from the CNS category and the second is from the GI segment. Japan is increasing the share of its healthcare spend on generics pharma and is targeting this share to go up to 30 per cent of its total market by 2013.